

Francesco Violi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5559230/publications.pdf>

Version: 2024-02-01

512
papers

20,028
citations

9264

74
h-index

24982

109
g-index

518
all docs

518
docs citations

518
times ranked

21479
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2023, 20, 24-37.	13.7	67
2	Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 155-165.	2.4	6
3	Toll-like receptor 4 activation in platelets from myocardial infarction patients. <i>Thrombosis Research</i> , 2022, 209, 33-40.	1.7	8
4	Interventional study with vitamin E in cardiovascular disease and meta-analysis. <i>Free Radical Biology and Medicine</i> , 2022, 178, 26-41.	2.9	32
5	Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 257-266.	3.4	18
6	Reply to Chen and Vitetta. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00448.	2.5	0
7	The ADA (Age-D-Dimer-Albumin) Score to Predict Thrombosis in SARS-CoV-2. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1567-1572.	3.4	11
8	Full <i>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis. <i>Haematologica</i> , 2022, 107, 1933-1939.	3.5	5
9	Aging-Related Decline of Autophagy in Patients with Atrial Fibrillation—A Post Hoc Analysis of the ATHERO-AF Study. <i>Antioxidants</i> , 2022, 11, 698.	5.1	5
10	Extra Virgin Olive Oil Reduces Gut Permeability and Metabolic Endotoxemia in Diabetic Patients. <i>Nutrients</i> , 2022, 14, 2153.	4.1	11
11	Sex-Related Differences in Oxidative, Platelet, and Vascular Function in Chronic Users of Heat-not-Burn vs. Traditional Combustion Cigarettes. <i>Antioxidants</i> , 2022, 11, 1237.	5.1	1
12	Is Albumin Predictor of Mortality in COVID-19?. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 139-142.	5.4	136
13	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2021, 46, 100410.	2.4	7
14	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. <i>International Journal of Cardiology</i> , 2021, 322, 245-249.	1.7	1
15	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13771.	1.7	14
16	Anticoagulation in patients with advanced liver disease: an open issue. <i>Internal and Emergency Medicine</i> , 2021, 16, 61-71.	2.0	7
17	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2021, 141, 1-6.	1.6	5
18	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2021, 96, 658-665.	3.0	22

#	ARTICLE	IF	CITATIONS
19	Waves of SARS-CoV-2 Infection and Blood Coagulationâ€”A Link and Beyond. <i>Thrombosis and Haemostasis</i> , 2021, 121, 004-006.	3.4	4
20	Sexâ€‘based difference in anticoagulated patients with mechanical prosthetic heart valves and longâ€‘term mortality risk. <i>International Journal of Clinical Practice</i> , 2021, 75, e14064.	1.7	1
21	Procedureâ€‘related bleeding risk in patients with cirrhosis and severe thrombocytopenia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13508.	3.4	20
22	Hypoalbuminemia and clinical adverse events in children with COVIDâ€‘19. <i>Journal of Medical Virology</i> , 2021, 93, 2611-2613.	5.0	7
23	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , 2021, 85, 80-85.	2.2	21
24	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 2063-2068.	2.0	5
25	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. <i>Pharmacological Research</i> , 2021, 165, 105418.	7.1	21
26	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients. <i>Italian Journal of Emergency Medicine</i> , 2021, 10, .	0.1	3
27	Beneficial effects of a combination of natural product activators of autophagy on endothelial cells and platelets. <i>British Journal of Pharmacology</i> , 2021, 178, 2146-2159.	5.4	15
28	Nox2 up-regulation and hypoalbuminemia in patients with type 2 diabetes mellitus. <i>Free Radical Biology and Medicine</i> , 2021, 168, 1-5.	2.9	5
29	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 28-36.	3.1	25
30	Low-Grade Endotoxemia and Thrombosis in COVID-19. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00348.	2.5	32
31	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , 2021, 12, 695961.	3.5	8
32	Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. <i>Platelets</i> , 2021, 32, 1009-1017.	2.3	12
33	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7193.	4.1	26
34	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. <i>Internal and Emergency Medicine</i> , 2021, 16, 1231-1237.	2.0	20
35	An observed association between conjunctivitis and severity of COVID-19. <i>Journal of Infection</i> , 2021, 83, 381-412.	3.3	8
36	Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2904-2911.	2.6	33

#	ARTICLE	IF	CITATIONS
37	Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns. HIV Medicine, 2021, 22, 434-444.	2.2	4
38	Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report. Thrombosis and Haemostasis, 2021, 121, 102-105.	3.4	36
39	Thrombosis in pre- and post-vaccination phase of COVID-19. European Heart Journal Supplements, 2021, 23, E184-E188.	0.1	5
40	Different rates of conjunctivitis in COVID-19 eastern and western hospitalized patients: a meta-analysis. Internal and Emergency Medicine, 2021, , 1.	2.0	2
41	COVID-19 and thrombosis: Clinical features, mechanism of disease, and therapeutic implications. Kardiologia Polska, 2021, 79, 1197-1205.	0.6	8
42	Effect of corticosteroids on myocardial injury among patients hospitalized for community-acquired pneumonia: rationale and study design. The colosseum trial. Internal and Emergency Medicine, 2020, 15, 79-86.	2.0	6
43	Oleuropein-enriched chocolate by extra virgin olive oil blunts hyperglycaemia in diabetic patients: Results from a one-time 2-hour post-prandial cross over study. Clinical Nutrition, 2020, 39, 2187-2191.	5.0	13
44	Clinical Cirrhosis Dilemmas: Survey of Practice from the 7th International Coagulation in Liver Disease Conference. Digestive Diseases and Sciences, 2020, 65, 1334-1339.	2.3	6
45	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. Internal and Emergency Medicine, 2020, 15, 135-143.	2.0	21
46	Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut, 2020, 69, 1535-1536.	12.1	42
47	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events: A Prospective Study. Clinical Gastroenterology and Hepatology, 2020, 18, 2324-2331.e4.	4.4	136
48	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. Mayo Clinic Proceedings, 2020, 95, 513-520.	3.0	11
49	Low-grade endotoxaemia enhances artery thrombus growth via Toll-like receptor 4: implication for myocardial infarction. European Heart Journal, 2020, 41, 3156-3165.	2.2	72
50	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology, 2020, 72, 470-485.	7.3	203
51	Family History of Atrial Fibrillation and Risk of Cardiovascular Events. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008477.	4.8	3
52	Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?. Drugs, 2020, 80, 1383-1396.	10.9	93
53	Nox2 activation in Covid-19. Redox Biology, 2020, 36, 101655.	9.0	114
54	Increased intestinal barrier permeability in patients with moderate to severe plaque-type psoriasis. Journal of Dermatology, 2020, 47, e366-e368.	1.2	7

#	ARTICLE	IF	CITATIONS
55	Is There an Association Between Atherosclerotic Burden, Oxidative Stress, and Gut-Derived Lipopolysaccharides?. Antioxidants and Redox Signaling, 2020, 33, 761-766.	5.4	13
56	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. British Journal of Clinical Pharmacology, 2020, 86, 2455-2463.	2.4	24
57	Nutrition, Thrombosis, and Cardiovascular Disease. Circulation Research, 2020, 126, 1415-1442.	4.5	35
58	Letter by Violi et al Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1". Circulation Research, 2020, 126, e114-e115.	4.5	1
59	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 866-875.	3.4	52
60	SARS-CoV-2 and myocardial injury: a role for Nox2?. Internal and Emergency Medicine, 2020, 15, 755-758.	2.0	18
61	Antiphospholipid antibodies in <scp>end-stage</scp> renal disease: A systematic review and <scp>meta-analysis</scp>. Hemodialysis International, 2020, 24, 383-396.	0.9	4
62	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 2020, 12, 1732.	4.1	33
63	COVID-19 and cardiovascular injury: A role for oxidative stress and antioxidant treatment?. International Journal of Cardiology, 2020, 312, 136.	1.7	27
64	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. Circulation Research, 2020, 127, 400-401.	4.5	60
65	Oxidative stress and gut-derived lipopolysaccharides in children affected by paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. BMC Pediatrics, 2020, 20, 127.	1.7	7
66	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. Haematologica, 2020, 105, 562-572.	3.5	81
67	Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHEROAF study. International Journal of Cancer, 2020, 147, 3424-3430.	5.1	8
68	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. Hepatology Communications, 2020, 4, 1034-1040.	4.3	22
69	Oxidative Stress and Gut-Derived Lipopolysaccharides in Neurodegenerative Disease: Role of NOX2. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-7.	4.0	42
70	Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2020, 11, e00116.	2.5	10
71	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. British Journal of Haematology, 2020, 190, 588-593.	2.5	14
72	Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis. Clinical and Translational Gastroenterology, 2020, 11, e00123.	2.5	30

#	ARTICLE	IF	CITATIONS
73	Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. <i>Thrombosis and Haemostasis</i> , 2020, 120, 949-956.	3.4	183
74	A novel role of MMP2 in regulating platelet NOX2 activation. <i>Free Radical Biology and Medicine</i> , 2020, 152, 355-362.	2.9	15
75	Conjunctivitis and COVID-19: A meta-analysis. <i>Journal of Medical Virology</i> , 2020, 92, 1413-1414.	5.0	129
76	Gut microbiota and myocardial infarction. <i>European Heart Journal</i> , 2020, 41, 2221-2222.	2.2	3
77	PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. <i>Antioxidants</i> , 2020, 9, 296.	5.1	28
78	Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil. <i>European Journal of Nutrition</i> , 2019, 58, 843-851.	3.9	25
79	Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. <i>Digestive and Liver Disease</i> , 2019, 51, 24-27.	0.9	25
80	Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 1325-1330.	5.4	20
81	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2301-2308.	3.9	15
82	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. <i>Atherosclerosis</i> , 2019, 289, 195-200.	0.8	12
83	Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 786-790.	5.4	4
84	Anticoagulants in Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2436.	2.8	0
85	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e012596.	3.7	23
86	Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients. <i>Thrombosis and Haemostasis</i> , 2019, 119, 496-499.	3.4	37
87	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	3.4	8
88	Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , 2019, 124, 723-728.	1.6	11
89	Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2019, 14, 1199-1201.	2.0	1
90	Enhanced NOX-2 derived oxidative stress in offspring of patients with early myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 293, 56-59.	1.7	17

#	ARTICLE	IF	CITATIONS
91	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. Journal of Alzheimer's Disease, 2019, 69, 561-576.	2.6	20
92	Acute Effects of Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome-VA Vascular Assessment of Proatherosclerotic Effects of Smoking (SURVA VAPES) 2 Randomized Trial. Journal of the American Heart Association, 2019, 8, e010455.	3.7	112
93	Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. Autoimmunity Reviews, 2019, 18, 519-525.	5.8	28
94	Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis. Hepatology Communications, 2019, 3, 504-512.	4.3	53
95	Antiplatelet Drugs in the Management of Thrombotic/Ischemic Events in Peripheral Artery Disease. , 2019, , 1059-1066.		1
96	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. Frontiers in Cardiovascular Medicine, 2019, 6, 17.	2.4	8
97	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. Biochemical Pharmacology, 2019, 163, 111-118.	4.4	16
98	Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. Liver International, 2019, 39, 885-893.	3.9	26
99	Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-acquired Pneumonia. Annals of the American Thoracic Society, 2019, 16, 91-98.	3.2	31
100	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. British Journal of Clinical Pharmacology, 2019, 85, 508-515.	2.4	19
101	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. Mayo Clinic Proceedings, 2019, 94, 1261-1267.	3.0	89
102	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. American Journal of Medicine, 2019, 132, 856-861.	1.5	67
103	Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study. Mayo Clinic Proceedings, 2019, 94, 37-43.	3.0	17
104	A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
105	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. World Journal of Gastroenterology, 2019, 25, 4172-4180.	3.3	23
106	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. European Journal of Case Reports in Internal Medicine, 2019, 6, 1.	0.4	1
107	Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque. Scientific Reports, 2018, 8, 3598.	3.3	88
108	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. European Journal of Internal Medicine, 2018, 54, 34-39.	2.2	18

#	ARTICLE	IF	CITATIONS
109	Antioxidant activity from extra virgin olive oil via inhibition of hydrogen peroxide-mediated NADPH-oxidase 2 activation. <i>Nutrition</i> , 2018, 55-56, 36-40.	2.4	13
110	Oleuropein, a component of extra virgin olive oil, lowers postprandial glycaemia in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1566-1574.	2.4	73
111	Editorial commentary: Nox2: A new challenge for antiplatelet treatment?. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 435-436.	4.9	2
112	Role of NADPH oxidase-2 and oxidative stress in children exposed to passive smoking. <i>Thorax</i> , 2018, 73, 986-988.	5.6	16
113	Reply. <i>Gastroenterology</i> , 2018, 154, 761-762.e1.	1.3	2
114	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 255, 69-73.	1.7	21
115	Response to Duret et al.. <i>American Journal of Gastroenterology</i> , 2018, 113, 775-776.	0.4	0
116	Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events. <i>Atherosclerosis</i> , 2018, 274, 29-34.	0.8	13
117	Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. <i>Pharmacological Research</i> , 2018, 132, 149-159.	7.1	9
118	Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia. <i>Pharmacological Research</i> , 2018, 131, 66-74.	7.1	10
119	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018, 13, 651-660.	2.0	29
120	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. <i>American Heart Journal</i> , 2018, 200, 32-36.	2.7	13
121	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>Data in Brief</i> , 2018, 17, 830-836.	1.0	5
122	Impaired platelet activation in patients with hereditary deficiency of p47 ^{phox} . <i>British Journal of Haematology</i> , 2018, 180, 454-456.	2.5	5
123	Does Regular Physical Exercise Preserve Artery Dilation by Lowering Nox2-Related Oxidative Stress?. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 1576-1581.	5.4	4
124	Early decrease of oxidative stress by non-invasive ventilation in patients with acute respiratory failure. <i>Internal and Emergency Medicine</i> , 2018, 13, 183-190.	2.0	9
125	Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study. <i>Journal of the American Heart Association</i> , 2018, 7, e009509.	3.7	9
126	Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2018, 7, 378.	2.4	36

#	ARTICLE	IF	CITATIONS
127	Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?. Thrombosis and Haemostasis, 2018, 118, 1847-1849.	3.4	1
128	Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481879356.	3.2	29
129	Passive Smoking Exacerbates Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Isoform 2â€“Induced Oxidative Stress and Arterial Dysfunction in Children with Persistent Allergic Rhinitis. Journal of Pediatrics, 2018, 202, 252-257.	1.8	9
130	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. International Journal of Cardiology, 2018, 264, 58-63.	1.7	69
131	A Closer Look at Platelet Count and Prediction of Bleeding in Cirrhotic Patients. American Journal of Gastroenterology, 2018, 113, 1397-1398.	0.4	0
132	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. Circulation Journal, 2018, 82, 1286-1292.	1.6	4
133	Interplay between Oxidative Stress and Platelet Activation in Coronary Thrombus of STEMI Patients. Antioxidants, 2018, 7, 83.	5.1	17
134	Hazelnut and cocoa spread improves flow-mediated dilatation in smokers. Internal and Emergency Medicine, 2018, 13, 1211-1217.	2.0	7
135	Extra virgin olive oil improves post-prandial glycemic and lipid profile in patients with impaired fasting glucose. Clinical Nutrition, 2017, 36, 782-787.	5.0	50
136	Antioxidant and antiplatelet activity by polyphenolâ€“rich nutrients: focus on extra virgin olive oil and cocoa. British Journal of Clinical Pharmacology, 2017, 83, 96-102.	2.4	48
137	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. International Journal of Cardiology, 2017, 231, 143-149.	1.7	22
138	Italian intersociety consensus on DOAC use in internal medicine. Internal and Emergency Medicine, 2017, 12, 387-406.	2.0	44
139	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renal disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. American Heart Journal, 2017, 189, 120-127.	2.7	10
140	Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology, 2017, 153, 480-487.e1.	1.3	301
141	Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 890-895.	2.6	26
142	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. Scientific Reports, 2017, 7, 3797.	3.3	8
143	Gutâ€“Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. Journal of the American Heart Association, 2017, 6, .	3.7	105
144	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis, 2017, 262, 179-184.	0.8	19

#	ARTICLE	IF	CITATIONS
145	Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2017, 64, 1486-1493.	5.8	162
146	Reply to: "Monitoring antivitamin K anticoagulants in antiphospholipid syndrome: A challenge in quality". <i>Atherosclerosis</i> , 2017, 256, 148-149.	0.8	0
147	NADPH Oxidase-2 and Atherothrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 218-225.	2.4	84
148	Are nutraceuticals the modern panacea? From myth to science. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 5-7.	2.4	21
149	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. <i>American Journal of Gastroenterology</i> , 2017, 112, 1832-1839.	0.4	109
150	Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 1083-1124.	5.4	92
151	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. <i>Internal and Emergency Medicine</i> , 2017, 12, 1159-1165.	2.0	16
152	Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1455-1462.	2.8	57
153	Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. <i>Journal of Hepatology</i> , 2017, 67, 950-956.	3.7	94
154	Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching*. <i>Critical Care Medicine</i> , 2017, 45, 1871-1879.	0.9	33
155	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. <i>Scientific Reports</i> , 2017, 7, 15756.	3.3	45
156	Letter by Violi et al Regarding Article, "Distinct Regulatory Effects of Myeloid Cell and Endothelial Cell NADPH Oxidase 2 on Blood Pressure". <i>Circulation</i> , 2017, 136, 2088-2089.	1.6	0
157	Low-grade endotoxemia and platelet activation in cirrhosis. <i>Hepatology</i> , 2017, 65, 571-581.	7.3	107
158	Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1558-1570.	3.4	56
159	Extra Virgin Olive Oil and Cardiovascular Diseases: Benefits for Human Health. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 18, 4-13.	1.2	95
160	NADPH Oxidase Deficiency: A Multisystem Approach. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-23.	4.0	29
161	Cirrhosis as a risk factor for venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2017, 117, 03-05.	3.4	24
162	Antiplatelet Therapy in Peripheral Artery Disease. , 2017, , 1381-1390.		0

#	ARTICLE	IF	CITATIONS
163	NOX 5 is expressed in platelets from patients with chronic granulomatous disease. <i>Thrombosis and Haemostasis</i> , 2016, 116, 198-200.	3.4	8
164	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 856-863.	3.4	30
165	Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 814-816.	2.0	0
166	Role of aspirin in patients with septic shock: a complex and intriguing relationship. <i>Intensive Care Medicine</i> , 2016, 42, 1097-1097.	8.2	1
167	Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. <i>Internal and Emergency Medicine</i> , 2016, 11, 1059-1066.	2.0	90
168	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	143
169	Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. <i>Diabetes Care</i> , 2016, 39, 1416-1423.	8.6	95
170	Sharing Clinical Data. <i>European Journal of Internal Medicine</i> , 2016, 32, e10.	2.2	0
171	Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials. <i>International Journal of Cardiology</i> , 2016, 212, 255-258.	1.7	19
172	Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. <i>Internal and Emergency Medicine</i> , 2016, 11, 637-648.	2.0	35
173	Acute Impact of Tobacco vs Electronic Cigarette Smoking on Oxidative Stress and Vascular Function. <i>Chest</i> , 2016, 150, 606-612.	0.8	292
174	Chronic granulomatous disease as an SOS call for multicenter cooperative effort to prevent infections. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 285-289.	1.0	7
175	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , 2016, 113, 484-489.	7.1	22
176	Low-grade endotoxemia and clotting activation in the early phase of pneumonia. <i>Respirology</i> , 2016, 21, 1465-1471.	2.3	29
177	Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2016, 223, 619-624.	1.7	11
178	Pentraxin 3 “A Link Between Obesity, Inflammation and Vascular Disease?”. <i>Circulation Journal</i> , 2016, 80, 327-328.	1.6	5
179	Endotoxemia as a trigger of thrombosis in cirrhosis. <i>Haematologica</i> , 2016, 101, e162-e163.	3.5	16
180	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 751-755.	5.4	15

#	ARTICLE	IF	CITATIONS
181	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2016, 36, 74-80.	2.2	15
182	Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	51
183	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. <i>Journal of Infection</i> , 2016, 73, 107-114.	3.3	45
184	Hospitalization for Pneumonia is Associated With Decreased 1-Year Survival in Patients With Type 2 Diabetes. <i>Medicine (United States)</i> , 2016, 95, e2531.	1.0	25
185	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists. <i>Medicine (United States)</i> , 2016, 95, e2895.	1.0	50
186	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , 2016, 8, 275-283.	1.5	36
187	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016, 48, 455-467.	0.9	57
188	Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination?. <i>Intensive Care Medicine</i> , 2016, 42, 301-302.	8.2	16
189	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. <i>Internal and Emergency Medicine</i> , 2016, 11, 199-204.	2.0	41
190	Reply to: "Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke". <i>International Journal of Cardiology</i> , 2016, 202, 934-935.	1.7	0
191	Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. <i>Atherosclerosis</i> , 2016, 244, 48-50.	0.8	14
192	Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. <i>Oncotarget</i> , 2016, 7, 39143-39147.	1.8	18
193	Should the Term "Coagulopathy in Cirrhosis" Be Abandoned?. <i>JAMA Internal Medicine</i> , 2015, 175, 862.	5.1	13
194	Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. <i>Thrombosis and Haemostasis</i> , 2015, 114, 876-882.	3.4	17
195	Response to "Oxidative stress in patients affected by primary aldosteronism". <i>Journal of Hypertension</i> , 2015, 33, 884.	0.5	0
196	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 617-624.	3.4	50
197	Does Lysosomal Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28014-28021.	4.1	18
198	Atrial fibrillation is not associated with increased risk of venous thromboembolism: Results from ARAPACIS study. <i>Thrombosis and Haemostasis</i> , 2015, 114, 655-655.	3.4	2

#	ARTICLE	IF	CITATIONS
199	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. <i>World Journal of Hepatology</i> , 2015, 7, 1325.	2.0	152
200	Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. <i>Chest</i> , 2015, 147, 1644-1650.	0.8	59
201	HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. <i>Journal of Infection</i> , 2015, 70, 651-658.	3.3	17
202	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , 2015, 5, e008026-e008026.	1.9	21
203	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2015, 116, 647-651.	1.6	110
204	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. <i>Europace</i> , 2015, 17, 1223-1228.	1.7	13
205	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 490-497.e1.	2.7	26
206	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). <i>Europace</i> , 2015, 17, 1747-1769.	1.7	119
207	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , 2015, 70, 961-966.	5.6	38
208	New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials. <i>Internal and Emergency Medicine</i> , 2015, 10, 499-506.	2.0	19
209	Supplementation with vitamin E alone is associated with reduced myocardial infarction: A meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 354-363.	2.6	54
210	Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. <i>Digestive and Liver Disease</i> , 2015, 47, 429-431.	0.9	40
211	Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. <i>Atherosclerosis</i> , 2015, 238, 350-355.	0.8	30
212	Reducing the risk of hospital admission: A call to action from the Italian Society of Internal Medicine. <i>European Journal of Internal Medicine</i> , 2015, 26, 476-477.	2.2	2
213	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. <i>European Journal of Internal Medicine</i> , 2015, 26, e31-e33.	2.2	2
214	Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2015, 116, 877-882.	1.6	27
215	Lower Mortality Rate in Elderly Patients With Community-Onset Pneumonia on Treatment With Aspirin. <i>Journal of the American Heart Association</i> , 2015, 4, e001595.	3.7	78
216	Response to Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality. <i>International Journal of Cardiology</i> , 2015, 189, 247-248.	1.7	0

#	ARTICLE	IF	CITATIONS
217	Relation of Nonalcoholic Fatty Liver Disease and Framingham Risk Score to Flow-Mediated Dilation in Patients With Cardiometabolic Risk Factors. <i>American Journal of Cardiology</i> , 2015, 115, 1402-1406.	1.6	24
218	Endothelial dysfunction and oxidative stress in children with sleep disordered breathing: Role of NADPH oxidase. <i>Atherosclerosis</i> , 2015, 240, 222-227.	0.8	49
219	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1493-1494.	2.8	2
220	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. <i>European Journal of Internal Medicine</i> , 2015, 26, 243-249.	2.2	14
221	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. <i>European Journal of Internal Medicine</i> , 2015, 26, 330-337.	2.2	25
222	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1489-1490.	2.8	2
223	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1491-1492.	2.8	1
224	Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 682-687.	5.4	49
225	Nox-2 up-regulation and platelet activation: Novel insights. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 50-55.	1.9	32
226	Hospitalization for Pneumonia and Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1753.	7.4	3
227	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e113.	2.5	25
228	Reply to "The relation between flow mediated dilation and atrial fibrillation" by S. Balta. <i>International Journal of Cardiology</i> , 2015, 201, 225-226.	1.7	0
229	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. <i>EBioMedicine</i> , 2015, 2, 750-754.	6.1	51
230	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 201, 513-516.	1.7	57
231	Clinical Application of NOX Activity and Other Oxidative Biomarkers in Cardiovascular Disease: A Critical Review. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 514-532.	5.4	32
232	Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. <i>Clinical Nutrition</i> , 2015, 34, 899-903.	5.0	25
233	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 180, 1-5.	1.7	33
234	Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2015, 179, 139-143.	1.7	24

#	ARTICLE	IF	CITATIONS
235	Myocardial infarction and atrial fibrillation: Different impact of anti-IIa vs anti-Xa new oral anticoagulants. International Journal of Cardiology, 2015, 178, 8-9.	1.7	38
236	Individualizing Risk of Multidrug-Resistant Pathogens in Community-Onset Pneumonia. PLoS ONE, 2015, 10, e0119528.	2.5	55
237	Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.. Current Pharmaceutical Design, 2015, 21, 5945-5950.	1.9	5
238	Dipyridamole: A Drug with Unrecognized Antioxidant Activity. Current Topics in Medicinal Chemistry, 2015, 15, 822-829.	2.1	27
239	Abstract 16055: Ongoing Prothrombotic State in the Early Phase of Pneumonia. Circulation, 2015, 132, .	1.6	0
240	New Insights into the Steen Solution Properties: Breakthrough in Antioxidant Effects via NOX2 Downregulation. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-10.	4.0	25
241	Epicatechin and Catechin Modulate Endothelial Activation Induced by Platelets of Patients with Peripheral Artery Disease. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-9.	4.0	29
242	Platelet NOX, a novel target for anti-thrombotic treatment. Thrombosis and Haemostasis, 2014, 111, 817-823.	3.4	61
243	Total Adiponectin Is Inversely Associated with Platelet Activation and CHA ₂ DS ₂ -VASc Score in Anticoagulated Patients with Atrial Fibrillation. Mediators of Inflammation, 2014, 2014, 1-6.	3.0	19
244	Platelet Activation After Radiofrequency Ablation in Atrial Fibrillation. Circulation, 2014, 129, 5-7.	1.6	3
245	Does Enhancement of Oxidative Stress Markers Mediate Health Effects of Ambient Air Particles?. Antioxidants and Redox Signaling, 2014, 21, 46-51.	5.4	13
246	Clinical risk factors and subclinical target organ damage as predictors of new-onset of atrial fibrillation: The Catanzaro atrial fibrillation project. International Journal of Cardiology, 2014, 177, 666-668.	1.7	2
247	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and Emergency Medicine, 2014, 9, 723-734.	2.0	121
248	Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Internal and Emergency Medicine, 2014, 9, 861-870.	2.0	27
249	Dark Chocolate Acutely Improves Walking Autonomy in Patients With Peripheral Artery Disease. Journal of the American Heart Association, 2014, 3, .	3.7	62
250	Oxidative stress in patients affected by primary aldosteronism. Journal of Hypertension, 2014, 32, 2022-2029.	0.5	51
251	Different Degrees of NADPH Oxidase 2 Regulation and In Vivo Platelet Activation: Lesson From Chronic Granulomatous Disease. Journal of the American Heart Association, 2014, 3, e000920.	3.7	31
252	Aspirin Reload Before Elective Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 577-584.	3.9	17

#	ARTICLE	IF	CITATIONS
253	Role of platelets in NOX2 activation mediated by TNF α in heart failure. Internal and Emergency Medicine, 2014, 9, 179-185.	2.0	15
254	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. Digestive and Liver Disease, 2014, 46, 632-638.	0.9	11
255	Reply. Journal of the American College of Cardiology, 2014, 63, 1457-1458.	2.8	1
256	Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. Europace, 2014, 16, 1107-1116.	1.7	47
257	Statins as Regulators of Redox Signaling in Platelets. Antioxidants and Redox Signaling, 2014, 20, 1300-1312.	5.4	15
258	Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia. Journal of the American College of Cardiology, 2014, 64, 1917-1925.	2.8	134
259	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. European Journal of Internal Medicine, 2014, 25, 847-852.	2.2	1
260	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine, 2014, 25, 617-623.	2.2	75
261	Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. Atherosclerosis, 2014, 235, 649-658.	0.8	62
262	Identification and management of invasive mycoses in internal medicine: a road-map for physicians. Internal and Emergency Medicine, 2014, 9, 501-511.	2.0	23
263	NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology, 2014, 14, 81.	2.0	71
264	Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends in Cardiovascular Medicine, 2014, 24, 142-148.	4.9	34
265	Pneumonia, thrombosis and vascular disease. Journal of Thrombosis and Haemostasis, 2014, 12, 1391-1400.	3.8	56
266	Is NOX2 Upregulation Implicated in Myocardial Injury in Patients with Pneumonia?. Antioxidants and Redox Signaling, 2014, 20, 2949-2954.	5.4	25
267	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. European Journal of Internal Medicine, 2014, 25, 566-570.	2.2	23
268	LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism. Atherosclerosis, 2014, 237, 108-116.	0.8	91
269	Aldosterone-induced oxidative stress. Journal of Hypertension, 2014, 32, 2281.	0.5	2
270	Mechanisms And Management Of Thrombo-Embolic In Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 7, 1112.	0.5	24

#	ARTICLE	IF	CITATIONS
271	Abstract 16732: Urinary 11-Dehydro-Thromboxane B2 is Associated With Vascular and Non-Vascular Events in Atrial Fibrillation Patients. <i>Circulation</i> , 2014, 130, .	1.6	0
272	Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale. <i>Drugs and Aging</i> , 2013, 30, 103-112.	2.7	140
273	Prevalence of Peripheral Artery Disease by Abnormal Ankle-Brachial Index in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2255-2256.	2.8	49
274	Strong interplay between metabolic syndrome, obstructive sleep apnoea, oxidative stress and arterial dysfunction. <i>Sleep and Breathing</i> , 2013, 18, 223-4.	1.7	2
275	Interventional trials with anticoagulants in acutely ill medical patients: a methodological pitfall?. <i>Internal and Emergency Medicine</i> , 2013, 8, 461-464.	2.0	5
276	Does NADPH Oxidase Deficiency Cause Artery Dilatation in Humans?. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 1491-1496.	5.4	27
277	Statins as Antithrombotic Drugs. <i>Circulation</i> , 2013, 127, 251-257.	1.6	163
278	NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. <i>International Journal of Cardiology</i> , 2013, 165, 184-192.	1.7	51
279	Reduced Atherosclerotic Burden in Subjects With Genetically Determined Low Oxidative Stress. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 406-412.	2.4	52
280	Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013, 24, 800-806.	2.2	12
281	Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. <i>Atherosclerosis</i> , 2013, 231, 392-400.	0.8	43
282	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 3241-3247.	1.7	12
283	Moderate alcohol use and health: A consensus document. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 487-504.	2.6	120
284	Comment on "Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- α -lowering property". <i>Digestive and Liver Disease</i> , 2013, 45, 81-82.	0.9	1
285	Antithrombotic drugs in acutely ill medical patients: review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux. <i>Clinical Practice (London, England)</i> , 2013, 10, 615-627.	0.1	3
286	Letter by Violi et al Regarding Article, "Molecular Imaging of Inflammation and Platelet Adhesion in Advanced Atherosclerosis Effects of Antioxidant Therapy With NADPH Oxidase Inhibition". <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, e3.	2.6	0
287	Clotting Activation and Hyperfibrinolysis in Cirrhosis: Implication for Bleeding and Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 426-433.	2.7	45
288	Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 379-388.	1.0	15

#	ARTICLE	IF	CITATIONS
289	Vitamin E Serum Levels and Bleeding Risk in Patients Receiving Oral Anticoagulant Therapy: a Retrospective Cohort Study. <i>Journal of the American Heart Association</i> , 2013, 2, e000364.	3.7	36
290	Relationship Between Platelet and Urinary 8-iso-PGF2 α Levels in Subjects With Different Degrees of NOX2 Regulation. <i>Journal of the American Heart Association</i> , 2013, 2, e000198.	3.7	22
291	Weight Loss by Multidisciplinary Intervention Improves Endothelial and Sexual Function in Obese Fertile Women. <i>Journal of Sexual Medicine</i> , 2013, 10, 1024-1033.	0.6	38
292	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a "real-world" community cohort of patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1032-1038.	3.4	35
293	Early increase of NOX2-derived oxidative stress in children: relationship with age. <i>Pediatric Research</i> , 2013, 73, 788-793.	2.3	10
294	Treatment of a patient with congenital analbuminemia with atorvastatin and albumin infusion. <i>World Journal of Clinical Cases</i> , 2013, 1, 44.	0.8	14
295	Should all acutely ill medical patients be treated with antithrombotic drugs?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 589-595.	3.4	14
296	The expert in hemostasis and thrombosis in the Italian health system: role and requirements for a specific clinical and laboratory expertise. <i>Italian Journal of Medicine</i> , 2013, 7, 71.	0.3	0
297	Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. <i>Heart</i> , 2012, 98, 1063-1066.	2.9	32
298	Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin. <i>Diabetes</i> , 2012, 61, 1626-1632.	0.6	46
299	Serum Levels of Vitamin E Are Associated With Early Recurrence of Atrial Fibrillation After Electric Cardioversion. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 327-333.	4.8	16
300	Thromboembolism or Atherothromboembolism in Atrial Fibrillation?. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 1053-1055.	4.8	17
301	Obesity and Hypercholesterolemia are Associated with NOX2 Generated Oxidative Stress and Arterial Dysfunction. <i>Journal of Pediatrics</i> , 2012, 161, 1004-1009.	1.8	74
302	Platelet Oxidative Stress and Thrombosis. <i>Thrombosis Research</i> , 2012, 129, 378-381.	1.7	84
303	Antiplatelet Therapy in Peripheral Artery Disease. <i>Handbook of Experimental Pharmacology</i> , 2012, , 547-563.	1.8	11
304	"Pitfalls in assessing platelet activation status in patients with liver disease: authors' reply". <i>Liver International</i> , 2012, , .	3.9	0
305	Pitfalls in assessing platelet activation status in patients with liver disease: authors' reply. <i>Liver International</i> , 2012, 32, 1028-1028.	3.9	0
306	Reply to: Platelet function in patients with cirrhosis. <i>Journal of Hepatology</i> , 2012, 56, 994-995.	3.7	2

#	ARTICLE	IF	CITATIONS
307	Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovascular Disorders, 2012, 12, 107.	1.7	26
308	Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation. Biochemical Pharmacology, 2012, 84, 1635-1642.	4.4	33
309	Bleeding and thrombosis in cirrhotic patients: What really matters?. Digestive and Liver Disease, 2012, 44, 275-279.	0.9	34
310	Author reply to comment on "Bleeding and thrombosis in cirrhotic patients: What really matters?". Digestive and Liver Disease, 2012, 44, 1050.	0.9	0
311	Pneumonia in frail older patients: an up to date. Internal and Emergency Medicine, 2012, 7, 415-424.	2.0	30
312	Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. Journal of Vascular Surgery, 2012, 56, 1622-1628.e5.	1.1	18
313	Ultrasonography (US) and non-invasive diagnostic methods for non-alcoholic fatty liver disease (NAFLD) and early vascular damage. Possible application in a population study on the metabolic syndrome (MS). Internal and Emergency Medicine, 2012, 7, 283-290.	2.0	10
314	Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. BMC Pulmonary Medicine, 2012, 12, 36.	2.0	74
315	Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2. Circulation, 2012, 126, 92-103.	1.6	148
316	Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Internal and Emergency Medicine, 2012, 7, 219-227.	2.0	42
317	Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Internal and Emergency Medicine, 2012, 7, 213-218.	2.0	30
318	Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. Journal of Thrombosis and Haemostasis, 2012, 10, 125-132.	3.8	66
319	Polyphenolic Antioxidants and Health. , 2012, , 77-85.		4
320	Moderate Weight Loss Decreases Oxidative Stress and Increases Antioxidant Status in Patients with Metabolic Syndrome. ISRN Obesity, 2012, 2012, 1-9.	2.2	12
321	Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. Journal of Hepatology, 2011, 55, 1415-1427.	3.7	161
322	Ascorbic Acid Infusion Blunts CD40L Upregulation in Patients Undergoing Coronary Stent. Cardiovascular Therapeutics, 2011, 29, 385-394.	2.5	18
323	Effect of L-carnitine on oxidative stress and platelet activation after major surgery. Acta Anaesthesiologica Scandinavica, 2011, 55, 1022-1028.	1.6	23
324	NADPH oxidase-mediated platelet isoprostane overproduction in cirrhotic patients: implication for platelet activation. Liver International, 2011, 31, 1533-1540.	3.9	37

#	ARTICLE	IF	CITATIONS
325	Effects of resveratrol and other wine polyphenols on vascular function: an update. <i>Journal of Nutritional Biochemistry</i> , 2011, 22, 201-211.	4.2	144
326	Anoxia-Reoxygenation Enhances Platelet Thromboxane A ₂ Production via Reactive Oxygen Species-Generated NOX2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1766-1771.	2.4	35
327	NOX2-mediated arterial dysfunction in smokers: acute effect of dark chocolate. <i>Heart</i> , 2011, 97, 1776-1781.	2.9	55
328	Inherited Human gp91 ^{phox} Deficiency Is Associated With Impaired Isoprostane Formation and Platelet Dysfunction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 423-434.	2.4	124
329	The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. <i>Internal and Emergency Medicine</i> , 2010, 5, 91-94.	2.0	23
330	Intravenous Ascorbic Acid Infusion Improves Myocardial Perfusion Grade During Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 221-229.	2.9	64
331	Nutrition, Supplements, and Vitamins in Platelet Function and Bleeding. <i>Circulation</i> , 2010, 121, 1033-1044.	1.6	73
332	Letter by Violi et al Regarding Article, "Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization". <i>Circulation</i> , 2010, 122, e429; author reply e430.	1.6	0
333	Atorvastatin Inhibits gp91 ^{phox} Circulating Levels in Patients With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 360-367.	2.4	100
334	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2010, 363, 1185-1186.	27.0	51
335	The coagulopathy of chronic liver disease: Is there a causal relationship with bleeding? Yes. <i>European Journal of Internal Medicine</i> , 2010, 21, 62-64.	2.2	32
336	Obstructive sleep apnoea syndrome and the metabolic syndrome in an internal medicine setting. <i>European Journal of Internal Medicine</i> , 2010, 21, 191-195.	2.2	43
337	Poor vitamin B6 status: A novel potential thrombotic factor in chronic obstructive pulmonary disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, e17-e18.	2.6	1
338	Comparison of efficacy of antiplatelet treatments for patients with claudication. <i>Thrombosis and Haemostasis</i> , 2010, 103, 766-773.	3.4	26
339	Introduction to Nutraceuticals Special Issue. <i>Cardiovascular Therapeutics</i> , 2010, 28, 185-186.	2.5	1
340	Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2010, 213, 225-234.	0.8	49
341	Role of NADPH oxidase in atherosclerosis. <i>Future Cardiology</i> , 2009, 5, 83-92.	1.2	64
342	Hereditary Deficiency of gp91 ^{phox} Is Associated With Enhanced Arterial Dilatation. <i>Circulation</i> , 2009, 120, 1616-1622.	1.6	123

#	ARTICLE	IF	CITATIONS
343	Antioxidant Supplements and Cardiovascular Disease in Men. JAMA - Journal of the American Medical Association, 2009, 301, 1335.	7.4	2
344	Should we use anticoagulant drugs to treat portal vein thrombosis in patients with liver cirrhosis?. Internal and Emergency Medicine, 2009, 4, 163-164.	2.0	10
345	Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Alimentary Pharmacology and Therapeutics, 2009, 30, 444-451.	3.7	13
346	Chocolate, Lifestyle, and Health. Critical Reviews in Food Science and Nutrition, 2009, 49, 299-312.	10.3	78
347	Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 654-659.	2.6	39
348	The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidase in the Pathogenesis of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 87-92.	2.2	0
349	Myeloperoxidase overexpression in children with hypercholesterolemia. Atherosclerosis, 2009, 205, 239-243.	0.8	18
350	Hyperfibrinolysis in Liver Disease. Clinics in Liver Disease, 2009, 13, 21-31.	2.1	76
351	Portal vein thrombosis in liver cirrhosis. Internal and Emergency Medicine, 2008, 3, 213-218.	2.0	101
352	Aspirin in asymptomatic patients with a confirmed positivity of antiphospholipid antibodies. Internal and Emergency Medicine, 2008, 3, 373-374.	2.0	1
353	Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance. Journal of Thrombosis and Haemostasis, 2008, 6, 1832-1834.	3.8	13
354	Statins enhance circulating vitamin E. International Journal of Cardiology, 2008, 123, 172-174.	1.7	14
355	Association between venous and arterial thrombosis. Lancet, The, 2008, 371, 809.	13.7	2
356	Oxidative Stress Is Associated With Arterial Dysfunction and Enhanced Intima-Media Thickness in Children With Hypercholesterolemia: The Potential Role of Nicotinamide-Adenine Dinucleotide Phosphate Oxidase. Pediatrics, 2008, 122, e648-e655.	2.1	62
357	Letter by Violi and Pignatelli Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women's Health Study"; Circulation, 2008, 117, e312; author reply e313.	1.6	2
358	Tumour necrosis factor α upregulates platelet CD40L in patients with heart failure. Cardiovascular Research, 2008, 78, 515-522.	3.8	27
359	C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 752-757.	2.4	27
360	Effect of coffee drinking on platelets: inhibition of aggregation and phenols incorporation. British Journal of Nutrition, 2008, 100, 1276-1282.	2.3	69

#	ARTICLE	IF	CITATIONS
361	Resveratrol, at Concentrations Attainable with Moderate Wine Consumption, Stimulates Human Platelet Nitric Oxide Production ³ . Journal of Nutrition, 2008, 138, 1602-1608.	2.9	133
362	Statin Treatment as a Confounding Factor in Human Trials with Vitamin E. Journal of Nutrition, 2008, 138, 1179-1181.	2.9	13
363	Abstract 5454: Oxidative Stress is Associated with Arterial Dysfunction and Enhanced Intima-Media Thickness in Children with Hypercholesterolemia. Potential Role of NADPH Oxidase. Circulation, 2008, 118, .	1.6	0
364	LDL are oxidatively modified by platelets via GP91 phox and accumulate in human monocytes. FASEB Journal, 2007, 21, 927-934.	0.5	52
365	Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. European Heart Journal, 2007, 29, 54-62.	2.2	54
366	Soluble CD40 Ligand Predicts Ischemic Stroke and Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2763-2768.	2.4	75
367	Oxidative Stress in the Pathogenesis/Treatment of Atherosclerosis. Current Nutrition and Food Science, 2007, 3, 200-208.	0.6	3
368	Peripheral Arterial Disease and Oxidative Stress. Vascular Disease Prevention, 2007, 4, 1-5.	0.2	1
369	Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis, 2007, 191, 265-271.	0.8	131
370	Early Increase of Oxidative Stress and Soluble CD40L in Children With Hypercholesterolemia. Journal of the American College of Cardiology, 2007, 49, 1974-1981.	2.8	35
371	Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. Journal of Thrombosis and Haemostasis, 2007, 5, 1170-1178.	3.8	57
372	Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. Free Radical Biology and Medicine, 2007, 43, 853-859.	2.9	60
373	Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Internal and Emergency Medicine, 2007, 2, 24-28.	2.0	36
374	A critical review of antiplatelet treatment in peripheral arterial disease. Internal and Emergency Medicine, 2007, 2, 84-87.	2.0	6
375	A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vascular Health and Risk Management, 2007, 3, 93-8.	2.3	21
376	Aspirin resistance. Lancet, The, 2006, 367, 2059-2060.	13.7	5
377	Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Atherosclerosis, 2006, 188, 77-83.	0.8	171
378	Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: Effect of an antioxidant treatment. Journal of Vascular Surgery, 2006, 44, 525-530.	1.1	58

#	ARTICLE	IF	CITATIONS
379	Aspirin resistance: is this term meaningful?. <i>Current Opinion in Hematology</i> , 2006, 13, 331-336.	2.5	9
380	The need for a consistent definition of "aspirin resistance". <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1618-1619.	3.8	5
381	Hemostasis in chronic liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2065-2066.	3.8	3
382	99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 117-126.	6.4	78
383	Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation. <i>Diabetologia</i> , 2006, 49, 1169-1174.	6.3	45
384	Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. <i>European Heart Journal</i> , 2006, 28, 608-612.	2.2	105
385	Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism. <i>Cardiovascular Research</i> , 2006, 69, 218-226.	3.8	29
386	Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. <i>FASEB Journal</i> , 2006, 20, 1082-1089.	0.5	112
387	Nox2 Is Determinant for Ischemia-Induced Oxidative Stress and Arterial Vasodilatation: A Pilot Study in Patients With Hereditary Nox2 Deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, e131-2.	2.4	31
388	Alpha-Linolenic Acid-Rich Wheat Germ Oil Decreases Oxidative Stress and CD40 Ligand in Patients With Mild Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2577-2578.	2.4	53
389	Tumor necrosis factor- α as trigger of platelet activation in patients with heart failure. <i>Blood</i> , 2005, 106, 1992-1994.	1.4	94
390	Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2784-2789.	3.8	70
391	Vitamin C inhibits platelet expression of CD40 ligand. <i>Free Radical Biology and Medicine</i> , 2005, 38, 1662-1666.	2.9	40
392	Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. <i>Translational Research</i> , 2005, 146, 238-243.	2.3	53
393	Early Anticoagulant Effect of Atorvastatin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, e145; author reply e145-6.	2.4	0
394	Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1578-1582.	3.6	252
395	Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients. <i>Circulation</i> , 2005, 111, 412-419.	1.6	159
396	CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2005, 45, 35-42.	2.8	56

#	ARTICLE	IF	CITATIONS
397	The polyphenols quercetin and catechin synergize in inhibiting platelet CD40L expression. <i>Thrombosis and Haemostasis</i> , 2005, 94, 888-889.	3.4	15
398	Antioxidants and cardiovascular disease. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 895-900.	2.3	14
399	Premature Coronary Disease in Systemic Lupus. <i>New England Journal of Medicine</i> , 2004, 350, 1571-1575.	27.0	20
400	Should antioxidant status be considered in interventional trials with antioxidants?. <i>British Heart Journal</i> , 2004, 90, 598-602.	2.1	35
401	gp91phox-Dependent Expression of Platelet CD40 Ligand. <i>Circulation</i> , 2004, 110, 1326-1329.	1.6	137
402	Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. <i>European Heart Journal</i> , 2004, 25, 1845-1852.	2.2	119
403	Aspirin. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 335-336.	3.8	6
404	Vitamin E for the Treatment of Cardiovascular Disease: Is There a Future?. <i>Annals of the New York Academy of Sciences</i> , 2004, 1031, 292-304.	3.8	25
405	Future Directions in Preclinical Vitamin E Research: Panel Discussion A. <i>Annals of the New York Academy of Sciences</i> , 2004, 1031, 305-312.	3.8	3
406	Future Directions in Clinical Vitamin E Research: Panel Discussion B. <i>Annals of the New York Academy of Sciences</i> , 2004, 1031, 313-323.	3.8	1
407	Soluble CD154 plasma levels in patients with systemic lupus erythematosus: Modulation by antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2004, 50, 1693-1694.	6.7	15
408	Giant cell arteritis, oculomotor nerve palsy, and acute hearing loss. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 279-280.	1.1	19
409	Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. <i>Journal of the American College of Cardiology</i> , 2004, 43, 979-984.	2.8	130
410	Aspirin resistance and diabetic angiopathy: back to the future. <i>Thrombosis Research</i> , 2004, 113, 97-99.	1.7	18
411	Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia. <i>American Journal of Medicine</i> , 2004, 117, 803-804.	1.5	14
412	Enhanced platelet release of superoxide anion in systemic hypertension. <i>Journal of Hypertension</i> , 2004, 22, 1151-1156.	0.5	37
413	Antioxidants in Peripheral Arterial Disease. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2004, 4, 289-294.	2.0	7
414	Measurement of oxysterols and α -tocopherol in plasma and tissue samples as indices of oxidant stress status. <i>Analytical Biochemistry</i> , 2003, 312, 217-223.	2.4	129

#	ARTICLE	IF	CITATIONS
415	Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. Journal of Thrombosis and Haemostasis, 2003, 1, 523-531.	3.8	33
416	Fibrinogen as predictor of ischemic stroke in patients with non-valvular atrial fibrillation. Journal of Thrombosis and Haemostasis, 2003, 1, 2453-2455.	3.8	5
417	Enhanced TNF α and oxidative stress in patients with heart failure: effect of TNF α on platelet O ₂ - production. Thrombosis and Haemostasis, 2003, 90, 317-325.	3.4	58
418	Antioxidants in Peripheral Arterial Disease. Current Drug Targets, 2003, 4, 651-655.	2.1	4
419	Red and white wine differently affect collagen-induced platelet aggregation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 356-358.	0.3	25
420	Increased Superoxide Anion Production by Platelets in Hypercholesterolemic Patients. Thrombosis and Haemostasis, 2002, 87, 796-801.	3.4	46
421	Effect of vitamins E and C on transplant-associated atherosclerosis. Lancet, The, 2002, 360, 486.	13.7	0
422	MRC/BHF Heart Protection Study. Lancet, The, 2002, 360, 1782-1783.	13.7	12
423	Antioxidant treatment decreases the titer of circulating anticardiolipin antibodies: Comment on the article by Sambo et al. Arthritis and Rheumatism, 2002, 46, 3110-3112.	6.7	15
424	Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes/Metabolism Research and Reviews, 2002, 18, 156-159.	4.0	54
425	Other antiplatelet agents. , 2002, , 955-963.		0
426	Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets. Haematologica, 2002, 87, 420-6.	3.5	20
427	Angioplasty increases coronary sinus F ₂ -isoprostane formation: evidence for in vivo oxidative stress during PTCA. Journal of the American College of Cardiology, 2001, 37, 76-80.	2.8	110
428	Vitamin E supplementation. Lancet, The, 2001, 357, 632.	13.7	10
429	Antioxidant strategy for cardiovascular disease. Lancet, The, 2001, 357, 1704.	13.7	11
430	Clinical Trials with Vitamin E in Cardiovascular Disease: Are they Meaningful?. Thrombosis and Haemostasis, 2001, 86, 1121-1122.	3.4	5
431	Vitamin E, Atherosclerosis and Thrombosis. Thrombosis and Haemostasis, 2001, 85, 766-770.	3.4	17
432	Oxidant Stress in SLE Patients. , 2001, , 273-278.		0

#	ARTICLE	IF	CITATIONS
433	The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. American Journal of Clinical Nutrition, 2000, 72, 1150-1155.	4.7	244
434	Superoxide Anion and Hydroxyl Radical Release by Collagen-induced Platelet Aggregation - Role of Arachidonic Acid Metabolism. Thrombosis and Haemostasis, 2000, 83, 485-490.	3.4	90
435	Systemic cause of unstable atherosclerotic plaques. Lancet, The, 2000, 355, 1362.	13.7	1
436	Fluorescence quenching of dipyridamole associated to peroxyl radical scavenging: a versatile probe to measure the chain breaking antioxidant activity of biomolecules. Biochimica Et Biophysica Acta - General Subjects, 2000, 1474, 177-182.	2.4	33
437	Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis, 2000, 149, 111-116.	0.8	97
438	Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. Journal of the American College of Cardiology, 2000, 36, 427-431.	2.8	183
439	Clotting Activation after Transjugular Intrahepatic Portosystemic Stent Shunt. Thrombosis and Haemostasis, 1999, 81, 711-714.	3.4	8
440	Ongoing Prothrombotic State in Patients With Antiphospholipid Antibodies: A Role for Increased Lipid Peroxidation. Blood, 1999, 93, 3401-3407.	1.4	69
441	Vitamin E Reduces Monocyte Tissue Factor Expression in Cirrhotic Patients. Blood, 1999, 93, 2945-2950.	1.4	49
442	Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2542-2547.	2.4	46
443	Iron-Dependent Human Platelet Activation and Hydroxyl Radical Formation. Circulation, 1999, 99, 3118-3124.	1.6	105
444	Protection of low density lipoprotein oxidation by the antioxidant agent IRFI005, a new synthetic hydrophilic vitamin E analogue. Free Radical Biology and Medicine, 1999, 26, 858-868.	2.9	32
445	Vitamin E Reduces Monocyte Tissue Factor Expression in Cirrhotic Patients. Blood, 1999, 93, 2945-2950.	1.4	14
446	Oxygen Free Radical-Dependent Increased Platelet Function in β^2 -Thalassemia Major Patients. Thrombosis Research, 1998, 92, 283-286.	1.7	12
447	Chronic Obstructive Pulmonary Disease Is Associated with an Increase in Urinary Levels of Isoprostane $F_{2\pm}$ -III, an Index of Oxidant Stress. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1709-1714.	5.6	251
448	Increased Thromboxane Metabolites Excretion in Liver Cirrhosis. Thrombosis and Haemostasis, 1998, 79, 747-751.	3.4	29
449	Hydrogen Peroxide Is Involved in Collagen-Induced Platelet Activation. Blood, 1998, 91, 484-490.	1.4	278
450	Hydrogen Peroxide Is Involved in Collagen-Induced Platelet Activation. Blood, 1998, 91, 484-490.	1.4	8

#	ARTICLE	IF	CITATIONS
451	Enhanced Thromboxane Biosynthesis in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1794-1799.	5.6	69
452	Antioxidants and ischaemic heart disease. Lancet, The, 1997, 350, 667-668.	13.7	0
453	Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet, The, 1997, 350, 1222.	13.7	64
454	CAPRIE trial. Lancet, The, 1997, 349, 354.	13.7	11
455	Enhanced Lipid Peroxidation in Patients Positive for Antiphospholipid Antibodies. Blood, 1997, 90, 3931-3935.	1.4	107
456	Oxygen Free Radicals and Platelet Activation. Free Radical Biology and Medicine, 1997, 22, 999-1006.	2.9	211
457	Ongoing Prothrombotic State in the Portal Circulation of Cirrhotic Patients. Thrombosis and Haemostasis, 1997, 77, 044-047.	3.4	77
458	Platelet Activation by Superoxide Anion and Hydroxyl Radicals Intrinsically Generated by Platelets That Had Undergone Anoxia and Then Reoxygenated. Circulation, 1997, 95, 885-891.	1.6	126
459	Coexistence of Anti-Phospholipid Antibodies and Endothelial Perturbation in Systemic Lupus Erythematosus Patients With Ongoing Prothrombotic State. Circulation, 1997, 95, 1425-1432.	1.6	51
460	Diabetes Mellitus, Hypercholesterolemia, and Hypertension but Not Vascular Disease Per Se Are Associated With Persistent Platelet Activation In Vivo. Circulation, 1997, 96, 69-75.	1.6	180
461	Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis. Journal of Hepatology, 1996, 24, 574-580.	3.7	35
462	POTENTIAL USEFULNESS OF ANTIPLATELET AGENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Thrombosis Research, 1996, 84, 279-284.	1.7	2
463	Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. Atherosclerosis, 1996, 120, 25-35.	0.8	90
464	Preparation and biodistribution of 99mtechnetium labelled oxidized LDL in man. Atherosclerosis, 1996, 126, 131-141.	0.8	71
465	Local Amplification of Platelet Function by 8-Epi Prostaglandin F2Î± Is Not Mediated by Thromboxane Receptor Isoforms. Journal of Biological Chemistry, 1996, 271, 14916-14924.	3.4	180
466	High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia. Hepatology, 1996, 23, 1377-1383.	7.3	11
467	Association between High Values of D-dimer and Tissue-plasminogen Activator Activity and First Gastrointestinal Bleeding in Cirrhotic Patients. Thrombosis and Haemostasis, 1996, 76, 177-183.	3.4	58
468	Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. Hepatology, 1995, 22, 96-100.	7.3	24

#	ARTICLE	IF	CITATIONS
469	A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radical Biology and Medicine, 1995, 18, 239-247.	2.9	75
470	Thrombosis in the Antiphospholipid-Antibody Syndrome. New England Journal of Medicine, 1995, 333, 665-667.	27.0	29
471	Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology, 1995, 109, 531-539.	1.3	129
472	Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients*1. Hepatology, 1995, 22, 96-100.	7.3	11
473	Role of hydroxyl radicals in the activation of human platelets. FEBS Journal, 1994, 221, 695-704.	0.2	83
474	Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis. Clinica Chimica Acta, 1994, 224, 125-129.	1.1	14
475	Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. Journal of Hepatology, 1994, 20, 531-536.	3.7	80
476	Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels. Journal of Hepatology, 1994, 21, 1086-1091.	3.7	31
477	In Vivo Thrombin Generation and Platelet Hyperactivity in Patients with Chronic Obstructive Pulmonary Disease. Platelets, 1994, 5, 276-278.	2.3	6
478	Hypercoagulability State in Patients with Chronic Obstructive Pulmonary Disease. Thrombosis and Haemostasis, 1994, 72, 343-346.	3.4	62
479	Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ: British Medical Journal, 1994, 309, 239-240.	2.3	50
480	Hyperfibrinolysis Resulting from Clotting Activation in Patients with Different Degrees of Cirrhosis. Hepatology, 1993, 17, 78-83.	7.3	88
481	The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites. Biomedicine and Pharmacotherapy, 1993, 47, 345-352.	5.6	21
482	Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology, 1993, 17, 78-83.	7.3	1
483	Involvement of Phospholipase A2 in H2O2-dependent Platelet Activation. Platelets, 1992, 3, 87-90.	2.3	18
484	1-Year Survey of Patients with Advanced Liver Cirrhosis: Prognostic Value of Clinical and Laboratory Indexes Identified by the Cox Regression Model. Scandinavian Journal of Gastroenterology, 1992, 27, 852-856.	1.5	29
485	Improvement of blood gas levels after calcium-heparin treatment in patients with chronic obstructive pulmonary disease. Thrombosis Research, 1992, 68, 435-440.	1.7	1
486	Free radical-mediated platelet activation by hemoglobin released from red blood cells. Archives of Biochemistry and Biophysics, 1992, 299, 220-224.	3.0	73

#	ARTICLE	IF	CITATIONS
487	Mechanism of reaction of a suggested superoxide-dismutase mimic, Fe(II)-N,N,N,N-tetrakis(2-pyridylmethyl) ethylenediamine. Archives of Biochemistry and Biophysics, 1992, 293, 153-157.	3.0	30
488	Clotting Abnormalities in Chronic Liver Disease. Digestive Diseases, 1992, 10, 162-172.	1.9	22
489	Reaction of dipyridamole with the hydroxyl radical. Lipids, 1992, 27, 349-353.	1.7	58
490	Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology, 1992, 15, 672-676.	7.3	88
491	Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance. European Journal of Clinical Pharmacology, 1992, 42, 379-383.	1.9	12
492	Superoxide dismutase triggers activation of α -primed platelets. Archives of Biochemistry and Biophysics, 1991, 289, 180-183.	3.0	28
493	Specificity and sensitivity of diluted aPTT and anticardiolipin antibodies towards thrombosis and miscarriages in patients with systemic lupus erythematosus. Thrombosis Research, 1990, 59, 609-617.	1.7	5
494	Inhibition of cyclooxygenase-independent platelet aggregation by low vitamin E concentration. Atherosclerosis, 1990, 82, 247-252.	0.8	31
495	Dilute aPTT Prolongation by Antiphospholipid Antibodies in Patients with Liver Cirrhosis. Thrombosis and Haemostasis, 1990, 63, 183-186.	3.4	21
496	Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis.. Journal of Clinical Pathology, 1989, 42, 1246-1249.	2.0	16
497	Inhibition of Tissue Plasminogen Activator Inhibitor by Defibrotide in Atherosclerotic Patients. Seminars in Thrombosis and Hemostasis, 1989, 15, 226-229.	2.7	19
498	Inhibition of cyclooxygenase-independent platelet aggregation by sodium salicylate. Thrombosis Research, 1989, 54, 583-593.	1.7	4
499	Inhibition by picotamide of thromboxane production in vitro and ex vivo. European Journal of Clinical Pharmacology, 1988, 33, 599-602.	1.9	36
500	Human platelet aggregation by PAF and thromboxane production. Thrombosis Research, 1987, 48, 265-266.	1.7	8
501	Anticoagulant activity of anticardiolipin antibodies. Thrombosis Research, 1986, 44, 543-547.	1.7	29
502	Prekallikrein and Factor VII as Prognostic Indexes of Liver Failure. American Journal of Clinical Pathology, 1986, 85, 579-582.	0.7	28
503	Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.. Journal of Clinical Pathology, 1986, 39, 1003-1005.	2.0	5
504	Relationship between platelet cyclooxygenase pathway and plasma malondialdehyde-like material. Lipids, 1985, 20, 322-324.	1.7	6

#	ARTICLE	IF	CITATIONS
505	A simple method for evaluating platelet superoxide dismutase. Scandinavian Journal of Clinical and Laboratory Investigation, 1985, 45, 713-716.	1.2	7
506	Blood lipid profile in healthy subjects treated with ticlopidine. Atherosclerosis, 1985, 58, 291-294.	0.8	2
507	Apolipoproteins A-I, A-II and B in chronic active hepatitis and in liver cirrhotic patients. Clinica Chimica Acta, 1984, 137, 61-66.	1.1	21
508	The effects of gliclazide on platelet function in patients with diabetes mellitus. Current Medical Research and Opinion, 1982, 8, 200-203.	1.9	24
509	Influence of ascorbic acid on platelet aggregation in vitro and in vivo. Atherosclerosis, 1982, 41, 15-19.	0.8	28
510	Changes of the intralymphocytic sodium concentration after acute and chronic captopril administration. American Journal of Cardiology, 1982, 49, 1513-1514.	1.6	5
511	LONG-TERM OXYGEN AND ADVANCED CHRONIC BRONCHITIS. Lancet, The, 1981, 317, 1098.	13.7	6
512	TYPE-III HYPERLIPOPROTEINÆMIA. Lancet, The, 1977, 310, 355.	13.7	2